Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2, Lot RSV#007A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Brief Summary: Respiratory syncytial virus (RSV) is a common cause of illness in infants and children around the world. This study will evaluate the safety and immune response to an RSV vaccine in RSV-seronegative infants and children.

This study is a companion study to IMPAACT 2000.


Options:
A: Arm Label: RSV D46/NS2/N/ΔM2-2-HindIII Vaccine; Type: EXPERIMENTAL; Interventions: Biological: D46/NS2/N/ΔM2-2-HindIII | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: D46/NS2/N/ΔM2-2-HindIII; Assigned to Arm(s): RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: RSV LID ΔM2-2 Vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV LID ΔM2-2 Vaccine | Arm Label: Placebo Vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Vaccine | Intervention Type: BIOLOGICAL; Name: RSV LID ΔM2-2 Vaccine; Assigned to Arm(s): RSV LID ΔM2-2 Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine; Assigned to Arm(s): Placebo Vaccine
C: Arm Label: Rotavirus Vaccine at age 6 & 10 weeks; Type: ACTIVE_COMPARATOR; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 10 & 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 6,10,&14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Intervention Type: BIOLOGICAL; Name: Human Rotavirus Vaccine; Assigned to Arm(s): Rotavirus Vaccine at age 6 & 10 weeks, Rotavirus vaccine at age 10 & 14 weeks, Rotavirus vaccine at age 6,10,&14 weeks
D: Arm Label: Group 1: DS-Cav1 (50 mcg); Type: EXPERIMENTAL; Interventions: Biological: VRC-RSVRGP084-00-VP | Arm Label: Group 2: DS-Cav1 (50 mcg) + alum; Type: EXPERIMENTAL; Interventions: Biological: VRC-RSVRGP084-00-VP, Other: Aluminum Hydroxide Suspension | Arm Label: Group 3: DS-Cav1 (150 mcg); Type: EXPERIMENTAL; Interventions: Biological: VRC-RSVRGP084-00-VP | Arm Label: Group 4: DS-Cav1 (150 mcg) + alum; Type: EXPERIMENTAL; Interventions: Biological: VRC-RSVRGP084-00-VP, Other: Aluminum Hydroxide Suspension | Arm Label: Group 5: DS-Cav1 (500 mcg); Type: EXPERIMENTAL; Interventions: Biological: VRC-RSVRGP084-00-VP | Arm Label: Group 6:DS-Cav1 (500 mcg) + alum; Type: EXPERIMENTAL; Interventions: Biological: VRC-RSVRGP084-00-VP, Other: Aluminum Hydroxide Suspension | Intervention Type: BIOLOGICAL; Name: VRC-RSVRGP084-00-VP; Assigned to Arm(s): Group 1: DS-Cav1 (50 mcg), Group 2: DS-Cav1 (50 mcg) + alum, Group 3: DS-Cav1 (150 mcg), Group 4: DS-Cav1 (150 mcg) + alum, Group 5: DS-Cav1 (500 mcg), Group 6:DS-Cav1 (500 mcg) + alum | Intervention Type: OTHER; Name: Aluminum Hydroxide Suspension; Assigned to Arm(s): Group 2: DS-Cav1 (50 mcg) + alum, Group 4: DS-Cav1 (150 mcg) + alum, Group 6:DS-Cav1 (500 mcg) + alum

Answer: B